

5151 CORPORATE WAY JUPITER, FL 33458-3101 (866)720-8386

	VIEDICAL LABS-										
Client: LA VITALITY		20783	Patient:	NOACK, AI	OAM						
9301 Wilshire Blvd						Age:26 Sex	:M				
404			Address 1:	· /		Fasting:					
BEVERLY HILLS, CA	90210		Address 2:			υ					
Phys: KAWESCH, GARY	(561) 425	-6354	City:		State:	Zip: Page	e:1				
Acc# 003627983	Coll. Date: 09/08/22		Recv. Date: (		Print Date: 09/12						
Chart# Coll. Time: 09:17 AM		Recv. Time:11:48 AM		Print Time: 11:18							
First reported on:	09/09/22 08:30	<u> </u>	Final report	date:	09/11/22						
Report Status: FINAL											
Test Name			Results		Reference Range	Units					
**************************************											
					reported: 09/09	/22 08:14					
A/G Ratio			2.7	н	1.2 - 2.2		*1				
******											
					reported: 09/09/22 08:14						
CBC With Differential/Pla	atelet										
WBC			5.1		3.4 - 10.8	x10E3/uL	*1				
RBC			5.01		4.14 - 5.80	x10E6/uL	*1				
Hemoglobin			14.6		13.0 - 17.7	g/dL	*1				
Hematocrit			44.3		37.5 - 51.0	%	*1				
MCV			88		79 – 97	fL	*1				
MCH			29.1		26.6 - 33.0	pg	*1				
MCHC			33.0		31.5 - 35.7	g/dL	*1				
RDW			12.3		11.6 - 15.4	% 10F2/ I	*1				
Platelets			184		150 - 450	x10E3/uL	*1				
Neutrophils			58		Not Estab.	%	*1				
Lymphs			31		Not Estab.	%	*1				
Monocytes			8		Not Estab.	%	*1				
Eos Basos			2		Not Estab.	%	*1				
			1		Not Estab.	% 10E2/I	*1 *1				
Neutrophils (Absolute) Lymphs (Absolute)			3.0		1.4 - 7.0	x10E3/uL	*1 *1				
Monocytes(Absolute)			1.6 0.4		0.7 - 3.1 $0.1 - 0.9$	x10E3/uL	*1				
Eos (Absolute)			0.4		0.1 - 0.9 $0.0 - 0.4$	x10E3/uL x10E3/uL	*1				
Baso (Absolute)			0.1		0.0 - 0.4 $0.0 - 0.2$	x10E3/uL x10E3/uL	*1				
Immature Granulocytes			0.1		Not Estab.	%	*1				
Immature Grant (Abs)			0.0		0.0 - 0.1	x10E3/uL	*1				
Timilature Grans (1103)			0.0		0.0 0.1	KIOL5/UL	1				
					reported: 09/09	/22 08:14					
Comp. Metabolic Panel (	14)										
Glucose			93		65 - 99	mg/dL	*1				
BUN			17		6 - 20	mg/dL	*1				
Creatinine			0.84		0.76 - 1.27	mg/dL	*1				
eGFR			123		>59	mL/min/1.7	*1				
BUN/Creatinine Ratio			20		9 – 20		*1				
Sodium			140		134 - 144	mmol/L	*1				
Potassium	(0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1		4.5		3.5 - 5.2	mmol/L	*1				
	(Continued on I	Next Page)	)								



5151 CORPORATE WAY JUPITER, FL 33458-3101 (866)720-8386

	MEDICAL LABS-		(655)/25 5555						
Client: <b>LA VITALITY</b> 9301 Wilshire Blvd 404 BEVERLY HILLS, CA		20783	Patient: NOACK, AD Phone: ( ) - Address 1: Address 2:	DOB. 10/04/1995	Age:26 S Fastir				
Phys: KAWESCH, GARY	(561) 425	-6354	City:	State: Zip	o: Pa	ige:2			
Acc# 003627983 Chart# First reported on: Report Status: FINAL	Coll. Date: 09/08/22 Coll. Time: 09:17 AM 09/09/22 08:30		Recv. Date: 09/08/22 Recv. Time:11:48 AM Final report date:	Print Date: 09/12/2 Print Time: 11:18 09/11/22	2				
Test Name			Results	Reference Range	Units				
******** (Continued)									
Chloride Carbon Dioxide, Total Calcium Protein, Total Albumin Globulin, Total A/G Ratio Bilirubin, Total Alkaline Phosphatase AST (SGOT) ALT (SGPT)  Lipid Panel Cholesterol, Total Triglycerides HDL Cholesterol VLDL Cholesterol Cal LDL Chol Calc (NIH) Prostate Specific Ag			104 23 9.1 6.7 4.9 1.8 2.7 H 0.3 61 18 21 174 57 71 11 92	96 - 106 20 - 29 8.7 - 10.2 6.0 - 8.5 4.1 - 5.2 1.5 - 4.5 1.2 - 2.2 0.0 - 1.2 44 - 121 0 - 40 0 - 44 reported: 09/09/2: 100 - 199 0 - 149 >39 5 - 40 0 - 99 reported: 09/09/2: 0.0 - 4.0	mg/dL mg/dL mg/dL mg/dL mg/dL	*1 *1 *1 *1 *1 *1 *1 *1 *1 *1 *1 *1 *1 *			
TSH FSH  Luteinizing Hormone(LF	According to the decrease and resprostatectomy.  PSA value 0.2 repsa value 0.2 repsa value of the presence of	Roche ECLIA methodology.  According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.  Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.  reported: 09/09/22 08:14  1.040 0.450 - 4.500 uIU/mL *1 reported: 09/09/22 08:14  4.2 1.5 - 12.4 mIU/mL *1 reported: 09/09/22 08:14  4.3 1.7 - 8.6 mIU/mL *1 (Continued on Next Page)							
	(Continued on I	vevi Lab	;c)						



Client: LA VITALITY

5151 CORPORATE WAY JUPITER, FL 33458-3101 (866)720-8386

NOACK, ADAM

Director: Alan Sara, M.D

9301 Wilshire Blvd Phone: ( ) -DOB. 10/04/1995 Age:26 Sex: M 404 Address 1: Fasting: N BEVERLY HILLS, CA 90210 Address 2: (561) 425-6354 Phys: KAWESCH, GARY City: State: Zip: Page:3 Acc# 003627983 Coll. Date: 09/08/22 Recv. Date: 09/08/22 Print Date: 09/12/22 Chart# Coll. Time: 09:17 AM Recv. Time:11:48 AM Print Time: 11:18 09/09/22 08:30 09/11/22 First reported on: Final report date: Report Status: FINAL **Test Name** Results Units Reference Range \*\*\*\*\*\* (Continued) reported: 09/09/22 08:14 Estradiol \*1 28.5 7.6 - 42.6 pg/mL Roche ECLIA methodology reported: 09/09/22 11:07 **Testosterone Free, Profile I** Testosterone 591 264 - 916 ng/dL \*1 Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. Sex Horm Binding Glob, Serum 36.6 16.5 - 55.9 nmol/L \*1 Testost., Free, Calc 111.6 47.7 - 173.9 \*1 pg/mL reported: 09/11/22 08:06 IGF-1 Insulin-Like Growth Factor I 228 101 - 307 \*1 ng/mL **COMMENTS:** \_\_ END OF REPORT \_\_\_\_\_ \*1) Unless otherwise noted, Tests Performed at: LABCORP, 5610 WEST LA SALLE STREET, TAMPA, FL 33607

20783

Patient:

